WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 59'5701 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 44'4621 Child (under 5 years) mortality rate: 52

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 23'050  22'741  22'404  22'037  21'645  19'259  17'097  14'708 
Births 305  302  299  294  289  249  255  228 
Surviving infants 304  301  297  293  288  248  253  226 
Pop. less than 5 years 1'539  1'505  1'458  1'423  1'384  1'290  1'262  1'135 
Pop. less than 15 years 4'389  4'321  4'244  4'201  4'156  3'995  3'767  3'715 
Female 15-49 years 5'590  5'559  5'522  5'452  5'373  4'922  4'518  3'670 

Number of reported case

(Click for retrospective incidence data for Australia)
Diphtheria
Japanese encephalitis
Measles 199  190  70  104  65  108  880 
Mumps 195  145  89  164  286  212 
Pertussis 23'855  38'040  34'285  29'545  14'435  5'795  862  124 
Polio*
Rubella 35  60  42  25  38  313 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total)
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Australia)
Vaccine year result method % card seen                                                
BCG         
DTP1          92  92 
DTP3          92  92  92  92  92  90  95  33 
HepB_BD         
HepB3          92  92  92  92  94 
Hib3          92  92  92  92  94  90 
JapEnc         
MCV          94  94  94  94  94  91  86 
MCV2          91  90  88  83  80 
PCV1          91 
PCV3          91  91 
Pol3          92  92  92  92  92  90  72  17 
Rota1          84 
Rota_last          84  85  81 
Rubella1          94  94  94  94  94 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Australia)
DTP1 92  92  97  97  97  96  98  58 
DTP3 92  92  92  92  92  90  95  33 
HepB3 92  92  92  92  94 
Hib3 92  92  92  92  94  90 
MCV 94  94  94  94  94  91  86 
PCV3 91  91  91  91  91 
Pol3 92  92  92  92  92  90  72  17 
Rota_last 84  85  84  82  81 

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 100
From 80 to 89% 0
From 50 to 79% 0
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DTaPHibHepIPV 2, 4, 6 months; No
HPV 12-13 years (x3 doses); Yes
HepA 1-5 years; Yes Aboriginal and Torres Strait Islander children in Queensland, Northern Territory, Western Australia and South Australia
HepB birth-7 days; 10-14 years (x2 doses 6 months apart); No
Hib 12 months; No
HibHepB 2, 4, 12 months; No
IPV 2, 4, 6 months; 4 years; Yes
Influenza No Medically at risk
MMR 12 months; 4 years; No
MenC_conj 12 months; Yes
Pneumo_conj 2, 4, 6, 12-24 months; Yes 12M - 24M medically at risk and Aboriginal and Torres Strait Islander children
Pneumo_ps 4 years; >=50 years; Yes 12M - 24M medically at risk and Aboriginal and Torres Strait Islander children
Rotavirus 2, 4, 6 months; No 3rd dose is dependent on the vaccine brand used
Tdap 15-17 years; Yes
Varicella 18 months, 10-14 years; Yes

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR Yes  Yes  Yes  No  No  No   
What years does the MYP cover? number 2009-2013      NA  NA  NA   
Nº of districts with microplans that include activities to raise immunization coverage number          

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 676   
Nº districts with DTP3 coverage >=80% number 676   
% of districts with DTP3 coverage >=80% From 0 to 100% 100  100  100  100  100  100   
Nº districts with measles (MCV1) coverage >=95% number    
% of districts with MCV1 coverage >=95% From 0 to 100% 13  25  25  50     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes   
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND No  No  No         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 100  NA  NA  100  100  100   

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.